Transcription

1

2 5 Research coordinators (4) 2 Budget advisors 1 Legal advisor

3 Research coordinators Annett Wolf Bodil Formark Caroline Grabbe Emma Roos af Hjelmsäter Fredrik Snellman Economist Carina Forsberg Budget advice Sussi Mikaelsson Legal counsellor Tina Nordström Contact:

4 Information - Advice service - Info meetings - Web info Link to external contacts Advice - Idea - Structure - Partners Support - Forms - Details - Documents - Writing Budget & contract Administrative support - Advice - Templates Support - Documents - Participation

5

6

7 Bottom-up Excellent science (Spetskompetens) Societal challenges (Samhälleliga utmaningar) Industrial leadership (Industriellt ledarskap) Top-down

8 Bottom-up European Research Council (ERC) Future and Emerging Technologies (FET) Marie-Sklodowska-Curie Actions Research Infrastructures Excellent science (Spetskompetens) Societal challenges (Samhälleliga utmaningar) Industrial leadership (Industriellt ledarskap) Health Food security, agriculture and forestry, water research, bioeconomy Energy Transport Climate, environment, resource and raw materials Societies Secure societies Top-down Information and Communication Technologies Nanotechnologies Advanced materials Biotechnology Advanced manufacturing and processing Space

9 IMPACT! Societal challenges Research Excellent science (Spetskompetens) (Samhälleliga utmaningar) Application Industrial leadership (Industriellt ledarskap)

10

11 Number of applications Mio Euro 30 H2020 4, ,4 0,8 3,4 1,7 1,4 0,4 3,0 2,0 1,0 0 0,0 FP7 (funded) ERC 14 (1) Programme Health SC 1 18 (7) 16 3 Programme other SC 2-7/LEIT/FET 28 (9) 2 5 People - ITN 21 (3) People - Fellow 13 (2) 1 People - other 7 (4) 1 funded rejected in review Mio Euro Coordinator UmU 9 5 1

12 ERC European Research Council (individual grants) Excellent science Societal challenges MSCA - Marie Sklodowska-Curie actions - Individual Fellowships (IF) Support for mobility of young and experienced researchers. - Innovative Training Networks (ITN) Joint research/doctoral training. - Research and Innovation Staff Exchange (RISE). - Co-fund of regional, national and international programmes for mobility. Industrial leadership FET Future and Emerging Technologies - Collaborative Research to open new fields of innovation. Research Infrastructures including E-infrastructures - Ensuring access to world class facilities.

13 Support Excellent Principal Investigators. Ground-breaking science with high ambitions and feasibility. No pre-determined priorities. Three main research domains; 1) Physical Sciences and Engineering 2) Life Sciences 3) Social Sciences and Humanities Grant Type Years after PhD Amount of Deadline ERC Starting Grant 2-7 years (5 years) Autumn 2016? ERC Consolidating Grant 7-12 years (5 years) 2 Feb 2016 ERC Advanced Grant (5 years) 1 Sep 2016

14 Strategic Programme 1 WP 1 Strategic Programme 2 WP 2 Strategic Programme 3 WP 3

15 Excellent science Societal challenges Industrial leadership

16 Societal challenges Excellent science Information and Communication Technologies Nanotechnologies Advanced materials Biotechnology Advanced manufacturing and processing Space Industrial leadership

17 EU participant portal

18

19

20

21

22 Flat rate for indirect costs: 25%

23

24

25 1. Understanding health, well-being and disease 2. Preventing disease 3. Treating and managing disease 4. Active ageing and self-management of health 5. Methods and Data 6. Health care provision and integrated care

26 EU Calls in Work Programme 2016/2017

27 Specific Challenge: Chronic diseases represent a significant burden on individuals and healthcare systems in the European Union and beyond. Innovative and effective therapeutic approaches are required to provide the best quality of care when prevention strategies fail. While considerable basic knowledge has been generated by biomedical research in recent years, the development of new therapies is stagnating, in part due to a lack of clinical validation. Expected Impact: New or optimized therapeutic strategies, adapted where relevant to the different needs of men, women, children and the elderly, with the highest potential to generate advances in clinical practice and care for chronic non-communicable or chronic infectious diseases. Improve the therapeutic outcome of major chronic health issues with significant impact on disease burden of individual patients and health care systems. The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately.

28 Specific Challenge: The activity aims at developing and validating radically new ICT based concepts and approaches for empowering and motivating people in need of guidance and care due to age related conditions, in cooperation with their carers where relevant, and to help them improve and maintain their independence, functional capacity, health status as well as preserving their physical, cognitive, mental and social well-being. Expected Impact: The proposal should present methodologies and metrics as appropriate for measuring its progress towards the expected impact in: Usefulness and effectiveness of personalized recommendations and follow-up in terms of the goals of preserving physical, cognitive, mental and social well-being for as long as possible; Validation of non-obtrusive technology for physical, cognitive, social and mental well-being; Evidence of user-centered design and innovation, new intuitive ways of human-computer interaction, and user acceptance; Potential cost-effectiveness due to enhanced self-care, life-style and care management. The Commission considers that proposals requesting a contribution from the EU of between EUR 3 and 4 million would allow this specific challenge to be addressed appropriately.

29 Specific Challenge: Despite the major advances in understanding disease in the post-genomic era, still a majority of all drugs are effective in only a limited number of patients. From a clinical perspective, implementing knowledge-based decisions on what therapeutics to use for which patients and, if relevant, in which combinations, are extremely challenging. The aspiration to provide more effective therapeutic interventions tailored to the individual or groups of individuals with common molecular phenotypes remains unfulfilled because of the variable response of individuals to such interventions. Patient stratification aims at grouping patients into disease sub-groups, where the specific pathological processes involved are better defined (clinical/molecular phenotypes). This will lead to the development of targeted therapies, optimizing the intervention to individual patients, thus achieving greater success in treating or curing the patient. Expected Impact: New models for patient stratification to inform clinical decision making. Accelerate the translation of biomedical and clinical research results to medical use. Increased cost-effectiveness of the novel concepts in comparison to already established practices. Increased research and innovation opportunities in this innovative industries-driven field, particularly small or mediumsized enterprises (SMEs). The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately.

30 (EUR 5 and 8 million) Specific Challenge: The development of new biotechnology-based products needs to be complemented with a scientifically valid identification of the potential hazards from these biomaterials to human health and to the environment, together with the monitoring and reduction of the risk that these new technologies pose. Current knowledge is still incomplete and the established methods may be inappropriate for specific materials in view of their eventual deployment. The necessary integration of physical, chemical, biochemical and clinical methods is an open challenge. Hence, future production system engineering requires development of integrated and validated methodologies as basis for an appropriate integrated risk management. Expected Impact: Development of comprehensive understanding of the properties, interaction and fate of engineered biomaterials in relation to human health and environment; Support to policy and decision making concerning biomaterials research in respect to various stakeholders Validated test methods and schemes for the identification of potential adverse effects from biomaterials Support to pre and co-normative activities, such as with reference to the implementation of the REACH regulation[[regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH).

31

32 1. Objectives 2. Relation to the work programme 3. Concept and methodology 4. Ambition Our tips: Focus on the CALL meet all aspects of the CALL! Refer to relevant EU policy. Give CREDIBILITY to the proposed approach. Highlight past achievements, refer to EU projects.

33 1. Expected impact 2. Measures to maximize impact - Dissemination, exploitation, open data, knowledge management, communication. Our tips: Meet ALL expected impacts of the call. Accentuate the INNOVATION potential (if relevant). Use evidence / chains of evidence. Be clear and specific. Backed up by activities in your work plan.

34 1. Work plan Work package description, deliverables 2. Management structure, milestones and procedures (including risk management) 3. Consortium as a whole 4. Resources to be committed Our tips Show coherence and effectiveness of the work plan. Show complementarity of participants within a consortium. Be clear and detailed. WHO, WHAT, HOW and WHEN?

35 Three categories are evaluated: 1) Scientific Excellence 2) Impact 3) Quality and efficiency of implementation Expert Individual Evaluation Report Proposal Expert Expert Expert Expert Individual Evaluation Report Individual Evaluation Report Individual Evaluation Report Consensus group Individual Evaluation Report Consensus Report

36 Coordinator support from Grants Office - Extensive support - Some travel money - Contact us!

37

38

39

40 Know the call stay on the call. Know EU Policies - and synchronize your application to them! Past/current EU-projects refer when relevant all aspects of the call. clear and stay focused IMPACT WHAT WHOM RISK MANAGEMENT Start in time!

41 Homepage:

42 Contact us early! The day before the deadline is too late. We suggest and comment you decide! Try to embrace the feedback it is a chance, not a judgement. We want to help you - not to make things more complicated!

43 Research coordinators Annett Wolf Bodil Formark Caroline Grabbe Emma Roos af Hjelmsäter Fredrik Snellman Economist Carina Forsberg Budget advice Sussi Mikaelsson Legal counsellor Tina Nordström Contact: